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ABSTRACT: Pancreatic cancer (PanCa) is a highly lethal disease
with a poor 5 year survival rate, less than 7%. It has a dismal
prognosis, and more than 50% of cases are detected at an advanced
and metastatic stage. Gemcitabine (GEM) is a gold standard
chemotherapy used for PanCa treatment. However, GEM-acquired
resistance in cancer cells is considered as a major setback for its
continued clinical implementation. This phenomenon is evidently
linked to de novo lipid synthesis. PanCa cells rely on de novo lipid
synthesis, which is a prime event in survival and one of the key
drivers for tumorigenesis, cancer progression, and drug resistance.
Thus, the depletion of lipogenesis or lipid metabolism can not only
improve treatment outcomes but also overcome chemoresistance,
which is an unmet clinical need. Toward this effort, our study
reports a unique paclitaxel−poly(lactic-co-glycolic acid) (PLGA) nanoparticles (PPNPs) formulation which can target lipid
metabolism and improve anticancer efficacy of GEM in PanCa cells. PPNPs inhibit excessive lipid formation and alter membrane
stability with compromised membrane integrity, which was confirmed by Fourier transform infrared and zeta potential
measurements. The effective interference of PPNPs in lipid metabolic signaling was determined by reduction in the expression of
FASN, ACC, lipin, and Cox-2 proteins. This molecular action profoundly enhances efficacy of GEM as evident through enhanced
inhibitory effects on the tumorigenic and metastasis assays in PanCa cells. These data clearly suggest that the ablation of lipid
metabolism might offer an innovative approach for the improved therapeutic outcome in PanCa patients.
■ INTRODUCTION
Pancreatic cancer (PanCa) remains a second deadliest cancer
related disease with an estimated 56,770 new cases and 45,750
deaths in the United States in 2019.1 It is highly lethal cancer
with a 5 year mortality rate of 95%. The majority of patients
are not eligible for surgery because of the advanced stage of
disease or metastasis to other vital organs. At this stage,
chemotherapy is highly advised rather radiation or surgery
alone. There are few chemotherapy regimens such as Gemzar
(gemcitabine), Abraxane (albumin-bound paclitaxel formula-
tion), FOLFOX (combination of folinic acid, fluorouracil, and
oxaliplatin), and FOLFIRINOX (combination of fluorouracil,
irinotecan, leucovorin, oxaliplatin, and folinic acid)2,3 that have
been widely used; however, none of them are efficient to
improve overall survival more than 6−12 months. Additionally,
cocktail chemotherapy regimen(s) introduce severe systemic
toxicities and drug resistance; thus, cancer cells do not respond
to these regimens. These events offer recurrence of disease or
highly aggressive and metastasis disease which is difficult to
tackle. Thus, there is an urgent clinical unmet need to
overcome such short fall in effective chemotherapy for PanCa.
The literature strongly shows that glucose and lipid
metabolism contribute poor patients’ survival.4−6 The
metabolic pathway is one of the distinct features of
tumorigenesis and cancer progression.7 During cancer develop-
ment, the de novo lipid synthesis gets triggered distinct from
normal cells, causing an increase in the production of fatty
acids.7−9 The synthesis of fatty acids in normal cells is at a
lower level.10,11 The increase in demand of energy is supplied
by an increase in the enzymes involved in lipogenesis, which
further form lipids, glucose, and amino acids, in turn, leading to
proliferation and differentiation of tumor cells.12,13 The
phospholipids generated after fatty acid synthesis play an
integral part in the formation of the cell membrane and some
of the them function as signaling molecules in different
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oncogenic pathways. In fact, some lipids can act as a biomarker
for cancer diagnosis as the lipid composition changes from
normal cells as compared to cancer cells.7−9,14
In the cytosol, citrate is broken down by adenosine
triphosphate (ATP) citrate lyase to form acetyl coenzyme A
(acetyl-CoA), which is an important lipid synthesis substrate.
Acetyl-CoA carboxylase (ACC) is responsible for conversion
of acetyl-CoA to malonyl-CoA. Fatty acid synthase (FASN)
further converts malonyl-CoA to palmitic acid and the
synthesis of fatty acid proceeds thereon.7−9,14 There have
been various findings related to apoptosis and growth arrest of
cancer cells, as FASN is inhibited.15,16 Supplementation of a
lipid synthesis inhibitor (5-(tetradecyloxy)-2-furoic acid) or
ACC/FASN inhibitor (cerulenin and irgasan) can be efficient
to reduce the proliferation and increase apoptosis in cancer
cells.3,15 In de novo lipid synthesis, sterol regulatory element-
binding protein-1 (SREBP-1)14,16 regulates the expression of
FASN and ACC, thus facilitating the production of lipids,
subsequently endorses proliferation of cancer cells. It has now
been increasingly accepted that targeting or modulating lipid
metabolism in cancer cells is an emerging therapeutic strategy.
To this end, several inhibitors/drugs have been developed and
tested in several preclinical and clinical trials (or trials are
ongoing). There are number of clinical trials underway to learn
the therapeutic benefit with inhibitors blocking lipid
metabolism. These include gemcitabine and a combination
of disulfiram (NCT02671890), paricalcitol (NCT02030860),
and simvastatin (NCT00944463). A recent study reports that
an FASN inhibitor, orlistat, with gemcitabine combination not
only stimulates cell-cycle arrest and apoptosis through
induction of ROS but also promotes gemcitabine uptake and
metabolism in PanCa cells.4
Chemotherapy is a standard form of treatment for PanCa.
Gemcitabine is the first-line chemotherapy agent which gets
converted to disphosphate (dFdCDP) and triphosphate
(dFdCTP) intracellularly. Inactivation of ribonucleotide
reductase, which is integral for DNA replication and inhibition
of DNA by dFdCDP, leads to apoptosis eventually by
incorporating itself into DNA.8,9 When the human concen-
trative nucleoside transporter (hCNT1) expression is at a
lower level, there is limited gemcitabine transport in cells.
Because gemcitabine is a hydrophilic drug which requires an
efficient transport to aid its uptake across the hydrophobic cell
membrane.17 Gemcitabine is metabolized by cytidine deami-
nase which causes the drug to be rapidly cleared, that is,
decreased circulation time leading to its reduced therapeutic
efficacy.18,19 In order to combat this, elevated doses of
gemcitabine have been administered that have caused toxic
effects such as nausea and difficulty in breathing. In order to
increase its bioavailability, different approaches have been
undertaken.19 Additionally, other efflux pumps such as P-
glycoprotein (P-gp) or multidrug resistant gene-1/5 (MDR-1
or MRP5) expression can hinder gemcitabine uptake because
of elevation of drug-resistant features.18 Treatment efficacy of
gemcitabine can be improved with agents that can alter the
expression of the transporters18,19 or by increased gemcitabine
uptake.20
A clinical trial of Nab-paclitaxel (abraxane, albumin-bound
paclitaxel nanoparticle) and gemcitabine proved that the
combination was more effective as compared to gemcitabine
alone in antitumor activity. Nab-paclitaxel is known to decrease
the cytidine deaminase responsible for gemcitabine metabo-
lism and thus improving its half-life within the body.21 Until
today, there is no study dealing with lipid metabolism in
conjunction with paclitaxel or paclitaxel with gemcitabine to
control the PanCa growth. Our laboratory has formulated a
unique paclitaxel−poly(lactic-co-glycolic acid) (PLGA) nano-
particles (PPNPs) formulation, containing PLGA, which is an
ideal carrier for drug delivery because of its features such as
biocompatibility and biodegradation,22 and pluronic F-127 that
has the capability to inhibit P-glycoprotein efflux for increasing
intracellular drug concentration.23 This study reports that our
novel PPNPs nanoformulation effectively altered lipid
metabolism in PanCa cells and enhanced therapeutic efficacy
of gemcitabine.
■ EXPERIMENTAL SECTION
Cell Culture. PanCa cell lines (HPAF-II and PANC-1)
were purchased from American Type Culture Collection
(ATCC; Manassas, VA, USA) and cultured in DMEM/F12 or
DMEM (HyClone Laboratories, Inc. South Logan, Utah,
USA) supplemented with 10% fetal bovine serum (Atlanta
Biologicals, GA, USA) and 1% (w/v) penicillin−streptomycin
(Gibco, Thermo Fisher Scientific, Grand Island, NY) at 37 °C
in a humidified atmosphere containing 5% CO2. Both cell lines
were maintained as mycoplasma-free and used within 4−6
months of resuscitation. Cells were trypsinized once they reach
70−80% confluency and seeded as per the required experi-
ments.
Preparation and Characterization of Paclitaxel-
Encapsulated PLGA Nanoparticles. Paclitaxel-encapsulated
PLGA nanoparticles (PPNPs) were prepared using a nano-
precipitation method as previously described.24 In brief, 200
mg of PVA (Sigma, P8136) was dissolved in 20 mL of Milli-Q
to achieve 1% PVA. To this solution, the organic phase
containing 90 mg of PLGA (Lactel Polymers, B6010-4) and 10
mg of paclitaxel in 5 mL of acetone was added dropwise and
left to stir overnight at 800 rpm. Then, 5 mg of poly(L-lysine)
(Sigma, P2636) and 5 mg of the F127 polymer (Sigma,
P2443) in 2 mL of Milli-Q were added dropwise to the
formulation to achieve a stable coating on nanoparticles.
Similarly, PLGA control formulation was generated without
paclitaxel in nanoparticle formulation. Particle size and zeta
potential measurement were performed based on the principle
of dynamic light scattering using a Zetasizer (Nano ZS,
Malvern Instruments, Malvern, UK). Measurements were
performed in triplicate using 10 μL of the sample and 990
μL of phosphate-buffered saline (PBS). The spherical particle
morphology of generated PPNPs was imaged using a JEOL
1210-JEM transmission electron microscope (JEOL Ltd,
Tokyo, Japan). In this study, 20 μL of 1 mg/mL PPNP
sample solution was placed on a shiny side of 200 mesh
formvar-coated copper grid (grid size: 97 μm; Ted Pella Inc,
Redding, CA). A 2% w/v of uranyl acetate solution contrast
stain solution was used to stain nanoparticles for better
visibility. These air-dried nanoparticles on the grid were
imaged at 100,000× following our published protocol.25
Rh123 Dye Exclusion Assay. Rh123 dye exclusion assay
was performed to test the extent of possibility of the drug to
internalize in cells. To examine this phenomenon, 0.5 million
PanCa cells were seeded in a 6-well plate and allowed them to
attach overnight. Cells were treated with 10 nM PTX or 10 nM
PPNPs for 24 h. Then, the cells were washed three times with
1× PBS and incubated with 100 μg of Rh123 dye (1 mg/mL
stock solution) for 30 min and imaged under a microscope or
Rh123 dye fluorescence in cells was quantified using flow
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cytometry. For visualization of Rh123 in cells, after incubation
with Rh123, cells were given PBS washes and visualized under
an AMF4300 EVOS FL Imaging System (Life Technologies,
Carlsbad, CA, USA). For semiquantification analysis of Rh123
dye in cells, after incubation with Rh123 dye, cells were
trypsinized and centrifuged to remove unbound dye present in
culture media and then injected 10,000 cells into a NovoCyte
Flow Cytometer (ACEA NovoCyte 1000, ACEA Biosciences,
Inc. San Diego, CA, USA). The dye quantification in cell
population was measured using an FITC channel (λex: 485 nm
and λem: 520 nm).
26
Cell Proliferation by xCELLigence. Cell proliferation of
PANC-1 and HPAF-II cells was carried out by xCELLigence
assay using real-time cell analyzer (RTCA) DP instrument
(Roche) to evaluate influence of PPNPs/GEM combination
treatment. For this assay, PanCa cell lines (6000 cells/well)
were seeded in E plates according to manufacturer’s
specifications.27 After 24 h (cells attached to plates), various
treatments (10 nM PTX, 10 nM PPNPs, 100 nM GEM, 10 nM
PPNPs + 50 nM GEM, and 10 nM PPNPs + 100 nM GEM or
controls) were introduced, and the study continued for 65 h.
The selection of 10 nM PTX or PPNPs and 100 nM GEM for
all in vitro studies was based on our previous study24,28 which
suggests that these concentrations are effective and influence
on molecular effects in PanCa cells.
Lipid Extraction and FT-IR Spectroscopy. For this
study, PanCa cells were replated (0.5 million cells/well) in a 6-
well plate in 2 mL of the respective medium. The cells were
allowed to attach to plates overnight and treated with 10 nM
PTX, 10 nM PPNPs, 100 nM GEM, and 10 nM PPNPs + 100
nM GEM for 24 h. Treatments with PBS and nanoparticles
alone (no paclitaxel) were considered as controls. After
treatment, cells containing plates were washed three times
with 1× PBS, trypsinized, and pelleted down at 2000 rpm
using a Sorvall ST 8 Centrifuge (Thermo Fisher Scientific,
Suzhou, China). The membrane lipids were extracted from
PanCa cell pellets following Bligh and Dyer protocol. To a cell
pellet, 250 μL of chloroform was added and vortexed, followed
by the addition of 16.8 μL of 6 M HCl and 250 μL of
chloroform, again samples were vortexed. About 250 μL of
water was added to this solution, vortexed, and centrifugation
was carried out for 2000 rpm using an Eppendorf centrifuge
5415C (Brinkmann Instruments, Inc., N. Y., USA) for 5 min.
Samples were incubated at 4 °C for 1 h and the lipid portions
were collected from the lower phase.29 To examine lipid profile
alternation in cancer cells with treatments, we employed
Fourier transform infrared (FT-IR) spectroscopy. For this,
equal amounts of lipid extracts (based on protein quantifica-
tion) were deposited on a diamond/ZnSe attenuated total
reflection crystal plate and allowed to air-dry. Then, FT-IR
spectra were obtained using a PerkinElmer Spectrum 100
FTIR spectrometer (Waltham, MA, USA) in the range from
4000 to 650 cm−1 with a resolution of 2 cm−1. Each spectrum
is an average of 32 scans.
Confocal Microscopy. Confocal microscopy was em-
ployed in order to test the effect of different treatment groups
on the cellular lipid membrane. In this study, PanCa cells were
seeded in chamber slides and after 70% confluency, cells were
treated with 10 nM PTX, 10 nM PPNPs, 100 nM GEM, and
10 nM PPNPs + 100 nM GEM or control groups for 24 h.
After treatment, 0.7 μL of stain was added to each well
containing 1 mL of media and incubated for 30 min. Triton X-
100 (0.1%) was used to permeabilize cells, followed by
washing twice with PBS. Cell Mask deep red plasma
membrane stain was used to stain the lipid membranes of
cells. Upon DAPI staining, VECTASHIELD Mounting
Medium (Vector Labs, Burlingame, CA, USA) with a coverslip
was used to mount the slides. The membrane disruption was
observed using a laser confocal microscope (Carl Zeiss LSM
710, Oberkochen, Germany).30
Western Blotting. To examine superior inhibitory
metabolic effects of PPNPs/GEM combination on cancer
cells, we performed immunoblotting. For this study, PANC-1
and HPAF-II were seeded in 100 mm dishes and
supplemented treatments: 10 nM PTX, 10 nM PPNPs, 100
nM GEM, and 10 nM PPNPs + 100 nM GEM combination
with control and PLGA formulation for 48 h. 2× SDS lysis
extraction buffer (Santa Cruz Biotechnology, Santa Cruz, CA)
was used to prepare protein lysates. Protein concentration was
quantified using Bradford assay. Cell lysate proteins were
separated by 10% SDS-PAGE gels, transferred on to a PVDF
membrane, followed by blocking with 1% BSA. Then,
membranes were probed for protein expression with antibod-
ies: Bax, Bcl-2, FASN, ACC, Cox-2, Lipin, ATP citrate lyase,
and β-actin, followed by specific secondary antibodies.31 The
bound antibodies were viewed under a UVP Gel Doc system.
Zeta Potential Measurement of Whole Cells. Zeta
potential of cancer cells after treating with 10 nM PTX and
PPNPs, 100 nM GEM, and 10 nM PPNPs + 100 nM GEM
combination with respect to their control and blank nano-
particle group was measured using a Zetasizer (Nano ZS,
Malvern Instruments, Malvern, UK). After 24 h treatment,
cells were washed three times with 1× PBS and trypsinized.
About 10 μL of the sample was diluted with 990 μL of PBS
before measurement. Zeta potential measurements were
performed in triplicate.
Figure 1. Structure and characterization of paclitaxel-encapsulated poly(lactic-co-glycolic acid) nanoparticles (PPNPs). (A) Schematic structure
illustration of PPNPs generated in the solvent evaporation and nanoprecipitation process. (B) Representative transmission electron microscopy
image of PPNPs. JEOL 2010-JEM was used to image nanoparticles at a direct magnification of 100,000× with the help of a 2%w/v uranyl acetate
EM stain solution. (C,D) Particle size and zeta potential measurements of blank PLGA NPs and PPNPs in a Zetasizer. Data represent the average
of triplicate measurements using 10 μL of the sample and 990 μL of PBS.
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Statistical Analysis. All the experimental data, statistical
analysis, and graphical representations were processed using
GraphPad Prism 5 (San Diego, CA) software. The data are
shown as an average of representation of triplicates and mean
± sem. Student’s t-test was applied to analyze the difference
between groups. *p < 0.05 or #p < 0.05 was considered
statistically significant in these tests.
■ RESULTS
Characterization of PPNPs. All physicochemical charac-
terization of PPNPs was conducted to confirm the
encapsulation of paclitaxel in PLGA NPs and it is consistent
with our previous reports.24 In brief, putative structure,
transmission electron microscopy image, and dynamic light
scattering measurements of PPNPs are presented in Figure 1.
The TEM image of PPNPs confirms its uniformity of particle
size and its distribution in the dried form. Similarly, the average
hydrodynamic particle size of control PLGA NPs and PPNPs
was found to be 160 ± 5 and 190 ± 3 nm, respectively. TEM-
based particles size appears to be smaller than dynamic light
scattering (DLS)-based particle size measurements. This
difference between TEM and DLS size variation may be due
to the difference in the measurement environment. DLS
measurements provide particle size in suspension, which may
represent higher because of hydrodynamic volume of polymers
and other formulation excipients, while TEM size indicates the
particles those were completely in the dried state. Zeta
potential was found to be −0.688 and −1.68 mV for these
nanoparticles. This confirms that paclitaxel encapsulation did
not significantly alter the particle size, distribution, and zeta
potential.
Chemosensitization Ability of PPNPs. Rh123 dye
exclusion assay can be extended to determine the chemo-
sensitization potential of the drug or formulation, which has
Figure 2. Drug efflux inhibition phenomenon evaluated by Rh123 dye exclusion assay. (A) Cancer cells were treated for 24 h with 10 nM PTX or
10 nM PPNPs and incubated with Rh123 for 30 min before visualizing them under a microscope to obtain representative images. Rh123 showed
more accumulation in treatment groups of PPNPs, indicating P-gp and drug export inhibition in this treatment group. (B) Mean fluorescence
intensity in an FL1 channel (488 excitation, blue laser, 530 ± 15 nm, FITC/GFP) was measured for treatment groups. PPNPs showed increased
fluorescence in both PanCa cells as compared to 10 nM PTX treatment, indicating that PTX in solution gets effluxed because of P-gp. Data are
presented as the mean ± SEM (n = 3). *p < 0.05 and #p < 0.05 represent the significant value compared to the control and PTX, respectively.
Figure 3. PPNPs/GEM combination inhibits proliferation of PanCa cells. Effect of PPNPs/GEM on proliferation of PanCa cells was determined
using xCELLigence. 10 nM PTX, 100 nM GEM, 10 nM PPNPs, 10 nM PPNPs/50 nM GEM, and 10 nM PPNPs/100 nM GEM were used for
treatment with respect to the control and blank PLGA formulation.
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been previously employed in our laboratory. Rh123 is a red
color dye that easily crosses the cell membrane and stains the
cytoplasm when cells express low P-gp or multidrug resistance
protein.32 On the other hand, there may be less Rh123 stain in
cells when cells express more P-gp. This represents that it acts
as a probe for a chemosensitizer, that is, more Rh123 access
means more drug can be accumulated in cells without pumping
out drug through exocytosis or exporters. This phenomenon
was evaluated by microscopy and flow cytometry methods.
In the microscopy method, PTX-treated PanCa cells show a
minimum uptake of Rh123 because of export of Rh123 due to
presence of P-gp/MDR proteins (transporters, responsible for
pumping out the drug) on cells (Figure 2A), whereas in PPNP-
treated cells, it appears to have significantly more Rh123 dye in
cells because of inhibition of P-gp efflux. To further confirm
these results, the flow cytometry method was employed. In the
flow cytometry method, the mean flow intensity values also
suggest an increase in Rh123 stain with PTX and a greater
increase with PPNPs (significant) compared to that of control
cells and PTX-treated cells (Figure 2B).
PPNPs Treatment Efficiently Enhances GEM Treat-
ment Efficacy in PanCa Cells. To examine if lipid
metabolism inhibition with PPNP treatment can be translated
into therapeutic benefit, functional assays such as cytotoxicity
were performed in GEM combination using HPAF-II and
PANC-1 cells (Figure 3). Proliferation is an inherent property
of cancer cells. To investigate the effect of PPNPs/GEM
combination treatment on PanCa cells, a real-time xCELLi-
gence assay was conducted (Figure 3). This assay provides the
cell index which is basically the electrical impedance due to the
presence of cells that indicate the growth of cells. The cell
index was continuously hiked in the control, PLGA NPs, and
GEM-treated groups, while PPNPs and PPNPs/GEM
combination treatment group effectively reduced the cell
index growth. The overall cell index growth was greatly
reduced by PPNPs/GEM combination treatment. However,
the effect of PPNPs (10 nM)/GEM (100 nM) combination is
more pronounced than PPNPs (10 nM)/GEM (50 nM).
Therefore, this data confirm that PPNPs (10 nM)/GEM (100
nM) exhibited a significant growth control over all other
treatments.
Spectral Analysis Confirms Reduction in Lipids with
PPNP Treatment. FT-IR spectra of the extracted lipids from
PanCa cell lines treated with various groups are presented in
Figure 4. The control cells exhibited two strong transmittance
peaks in the region 3000−2800 and 1740 cm−1 which are
characteristic of the lipid acyl chain (v-CH2 or v-CH3) on
unsaturated carbon and ester carbonyl (vibrational stretching),
respectively. Such a functional distinct characteristic peak was
reported to lipids in the literature.29 With treatments (PTX
and GEM), a slight decrease in lipid transmittance peaks was
observed. However, the PPNPs and combination group of
PPNPs (10 nM) and GEM (100 nM) showed greater impact
on the lipid structures as evident from the intensity of the
spectra in these peak regions. This result is indicating a
significant role of PPNPs in inhibition of lipid production in
pancreatic cells to enhance GEM efficacy.
Confocal Microscopy. FT-IR spectral analysis is an
indication of superior effects of PPNPs/GEM combination
on the lipid structure in cancer cells. However, the above-
mentioned study only refers to extracted cell membrane lipids
but do not represent intact cell membranes of cancer cells.
Therefore, a confocal microscopy study was performed to
delineate this aspect in whole cells. Cell Mask deep red plasma
Figure 4. PPNPs and PPNPs/GEM combination lower cellular lipid contents in PanCa cells. (A) FT-IR spectra of cellular lipids of PanCa cells that
were obtained after treatment with various groups. The lipid contents were extracted using Bligh and Dyer protocol and lipids. The spectral data
represent an average of 32 scans. (B) Graphical representation of the methyl (ester moiety) and −CH group (ester moiety) of cellular lipids upon
combination treatment. Data are indicated as the mean ± SEM (n = 6). *p < 0.05 and #p < 0.05 represent the significant value of treatment groups
compared to the control and the PPNPs/GEM group compared to other treatment groups, respectively.
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membrane stain is a dye that specifically illuminates the plasma
membrane upon incubation. This dye was used to observe
visual changes in the membrane with various treatments
(Figure 5). It was observed that with PTX and GEM drug
treatments, there was a decrease in lipid production (less lipid
stain) on cell membranes compared to the control groups
(PBS or PLGA). PPNPs treatment inhibited almost all lipid
production on the cell membrane, but the cell morphology is
round, whereas in the case of PPNPs/GEM combination
treatment, there was no lipid staining which indicates a
complete disruption of lipid membranes and/or inhibition of
lipid production.
PPNPs Alter Zeta Potential (Charge) on PanCa Cell
Membranes. To evaluate the combination treatment
enhancement effects, we focused on studying whole cell zeta
potential after treatments. Zeta potential is defined as the
electrostatic potential near the surface of a particle/material
which is corrected by charges of the opposite sign in the
environment. Chemotherapeutic agents and cell membrane
signals often may disturb the cellular membrane and their
integrity that can alter the surface zeta potential of the cancer
cells.33−36 Thus, in this study, the surface charge of the lipid
membrane that exists on HPAF-II and PANC-1’s cellular
membranes was determined after treatment with various
groups and compared with the control (Figure 6). The cancer
cells themselves present an initial zeta potential of −7.65 ± 0.4
(PANC-1) and −6.79 ± 0.3 (HPAF-II). There was no
significant change noticed in the zeta potentials upon
treatment with PTX and GEM. However, a noticeable change
in zeta potential was observed with PPNPs and PPNPs + GEM
treatments in HPAF-II and PANC-1 PanCa cells. Phosphati-
dylserine is a phospholipid which is present on the inner leaflet
of the lipid membrane. Before undergoing apoptosis, this
phospholipid is seen on the extracellular leaflet, giving the
signal that it is ready to undergo cell death.37 Our treatment of
PPNPs and PPNPs/GEM allows for flipping of phosphati-
dylserine from the inner to outer leaflet.
PPNPs Treatments Deregulate FASN-Mediated Lipid
Metabolism. PPNPs/GEM combination treatment leads to
alteration in lipid structures, which were determined by FT-IR
and confocal microscopy. To further delineate molecular
effects of the combination therapy on lipid metabolism, the
immunoblotting method was followed. Bax (a pro-apoptotic
protein) protein expression was found to be upregulated more
effectively with combination treatment as compared to the
control and alone drugs. Bcl-2 (an anti-apoptotic protein)
protein expression was decreased in the groups treated with
drugs alone, while combination treatment resulted in a
significant decrease (Figure 7). Protein expression of the
lipid metabolism pathway such as ACC, FASN, and Cox-2 was
confirmed to be downregulated with PPNPs alone and
PPNPs/GEM combination.38
■ DISCUSSION
Gemcitabine is an FDA approved first-line chemotherapeutic
agent for PanCa; however, its poor uptake and acquired
resistance show only marginal benefits in patients’ survival.18,19
Gemcitabine requires safe entry into the cell and becomes the
biologically active triphosphate form by phosphorylation. Such
a passive entry and accumulation of gemcitabine always
depend on mutational deficiency of nucleoside transporters.
To achieve therapeutic concentration at tumors, a huge dose of
gemcitabine (∼1000 mg/m2) needs to be administered
because of its poor half-life that leads to remarkable systemic
toxicities (kidney and liver dysfunctions). In spite, tumor
uptake of the drug is suboptimal due to high desmoplasia in
pancreatic tumors that elevate the issues related to drug
resistance. To increase the uptake and therapeutic ability, there
is a need for a novel strategy in order to deliver the drug
toward tumor site. Paclitaxel or its FDA-approved nano-
formulation (Abraxane) induces apoptosis in cancer cells at
Figure 5. PPNPs and PPNPs/GEM combination treatment disrupt plasma lipid membrane integrity in PanCa cells. Representative confocal
microscopy images of PanCa cells after treatment with PBS/no treatment, blank PLGA NPs, 10 nM PTX, 100 nM GEM, 10 nM PPNPs, and 10
nM PPNPs/100 nM GEM. Membrane integrity was shown by the Deep Red plasma membrane known to stain the plasma membrane. Decrease in
the intensity of the staining indicating disruption of the membrane due to treatment.
Figure 6. PPNPs/GEM treatment alters surface charge on PanCa
cells. Zeta potential measurements were performed on whole cell
suspension in PBS after 24 h treatment of PanCa cells with 10 nM
PTX, 100 nM GEM, 10 nM PPNPs, and 10 nM PPNPs/100 nM
GEM. No treatment and blank PLGA NPs served as the respective
control groups. PPNPs/GEM exhibits neutralization of the negatively
charged functional membrane. Data are represented as mean ± SEM
(n = 3).
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low nanomolar concentrations. Abraxane considered as the
first line of therapy in advanced breast, lung, and pancreatic
cancers along with gemcitabine or other chemotherapy agents.
Several therapeutic combinations are under clinical evaluation.
Paclitaxel treatment primarily stabilizes tubulin polymerization,
thus reducing tumor growth. Paclitaxel nanoparticles can also
facilitate gemcitabine internalization into tumors by softening
tumor tissue.39
The literature supports that strategic inhibition of lipid
metabolism or FASN in cancer cells promotes synergy with
chemotherapy.40 There is an evidence through the Cancer
Genome Atlas that among many pathways’ metabolic pathways
(lipid metabolism) is strongly linked to poor gemcitabine
response in PanCa patients.4,5 This eventually lowers
gemcitabine uptake, thus offering resistance and survival
nature in cancer cells. A recent study advices that strategic
inhibition of FASN with orlistat evidently decreases
gemcitabine metabolic activity and enhances the uptake by
cancer cells.4 Similarly, various lipid metabolism pathway
inhibitors promote apoptosis in cancer cells and a lower dose
of gemcitabine is required for effective therapy.
The current standard of therapy for PanCa is Nab-paclitaxel
combination with gemcitabine. This combination offers mean
survival time 13.3 months.41 There are a number of reasons
reported for such improved therapeutic benefits, including
enhanced level of gemcitabine uptake in tumor, decrease of
desmoplasia by nab-paclitaxel in tumors, and by activating
tumor angiogenesis that enhanced targetability of GEM at
tumor site. However, there is no evidence that paclitaxel plus
gemcitabine combination may regulate lipid metabolism. In
this attempt, we used our own paclitaxel nanoparticle
formulation (Figure 1). This is because our group has
constructed a unique nanoparticle formulation, that is,
PPNPs which can be further functionalized for targeted
delivery to pancreatic tumors. A recent report from our group
demonstrated that PPNPs can efficiently reduce tumor growth
in orthotopic tumor xenograft mouse models.24 Thus, in this
study, we delineated its effect on the lipid metabolism pathway
in PanCa cells (Figures 4−7).
The cellular membranes are primary impediment and the
first line of guard for the cell from their environments to
survive. This barrier limits the exchange of charged molecules
or ions across the cellular membrane and creates the cell
membrane potential. Such a cell membrane potential can act as
a distinguishable characteristic for cancerous cells compared to
normal cells. The literature indicates that cancerous cells
exhibit a higher degree of membrane negativity (a lower
cellular membrane potential) over normal cells because of their
rapid membrane changes, transformation, and fluidity.36
Another study demonstrated that a greater negative membrane
potential was observed for metastases (−35 mV) and primary
lesions (−25 mV) while quasi neutral for noncancer cells (0
mV).42 This advice change in the cellular membrane potential
can possibly determine its fate. Higher negative membrane
potential ultimately determines cancer cell’s zeta potential.
Chemotherapies can regulate such a phenomenon and alter the
membrane potential. This is evident from our zeta potential
values of cell membranes treated with PPNPs and PPNPs/
GEM combination treatment (Figure 6). All these events
demonstrate that PPNPs act as a anticancer drug that offers
apoptosis via modulation lipid metabolic pathways.
Drug uptake can be estimated through Rh123 dye exclusion
assay. Rh123 is a probe used for P-gp studies32 and here it
mimicked the role of gemcitabine. The PPNP treatment group
showed increased intensity with regard to uptake of Rh123,
confirming that our nanoformulation has the ability to inhibit
P-gp efflux of drugs (Figure 2) (gemcitabine) and, in turn,
increase its intracellular concentration, thus improving its
therapeutic efficacy (Figure 3). Our results suggest some lipid
modifications as the spectral intensity decreases for character-
istic lipid functional groups (Figure 4). Membrane dysregula-
tion was monitored by measuring the membrane charge and
integrity of the membrane with regard to the combination
therapy. The cell membrane is made up of different
phospholipids which are responsible for the charge on the
surface. Phosphatidylserine is one of the major phospholipids
present in the membrane component, and it undergoes
flipping, further leading to apoptosis.37 The combination
treatment quickens this flipping process, in turn, signaling the
apoptotic molecules. Alteration in the membrane was also
confirmed by confocal microscopy with the help of a dye that
stains the plasma membrane. Gemcitabine in combination with
our formulation showed decreased intensity of the membrane
stain. These results give us evidence that our combination of
PPNPs have the capability to alter the lipid membrane to
improve therapeutic efficacy of GEM (Figure 5).
In many cancers, dysregulation of lipid metabolism is often
linked to poor prognosis. Previous studies have shown that
inhibition of FASN has led to apoptosis in prostate,43 breast,44
and pancreatic4 cancers. Sun et al.,45 demonstrated that
SREBP-1, a master regulator of lipid metabolism (through
FASN and ACC), can ablate the tumorigenesis and
progression of PanCa. In this investigation, we performed
immunoblotting analysis to show the molecular effects of
PPNPs and PPNPs/GEM combination on certain key
regulators which are known to be upregulated in PanCa.4
These include FASN, ACC, Lipin, ATP citrate lyase, and Cox-
2. A significant downregulation of these proteins was noticed
with PPNPs and combination treatment compared with
controls (Figure 7). SREBP-1 regulates the activity of FASN
and ACC. The rate-limiting step in synthesis of fatty acids is
mediated by ACC. Our data showed a decrease in expression
Figure 7. Molecular effect of PPNPs and PPNPs/GEM on proteins
associated with lipid membrane metabolism in PanCa cells. Cell
lysates were collected after 48 h treatment with 10 nM PTX, 100 nM
GEM, 10 nM PPNPs, and 10 nM PPNPs/100 nM GEM. PBS and
blank PLGA NPs served as the respective control groups. Panel
showing decrease in ACC, FASN, Lipin, ATP citrate lyase, Cox-2, and
Bcl-2 expression and upregulation of Bax (apoptosis regulator) with
PPNPs and PPNPs and GEM combination.
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of FASN, a major enzyme responsible for elongation of fatty
acids and, in turn, causes progression of lipogenesis (Figure 7).
PLGA-based drug formulations are widely evaluated in a
number of clinical applications. This includes delivery of a
number of therapeutic molecules including paclitaxel. To the
best of our knowledge, the PPNPs delivery with gemcitabine
combination treatment would be the first report being used to
examine the lipid metabolism mechanism in PanCa. We also
noticed that SREBP-1-associated lipogenesis inhibition was
achieved with PPNPs and PPNPs/GEM combination to
control the cell growth and induction of apoptosis.
Altogether, our study suggests that PPNPs and PPNPs/
GEM combination can effectively inhibit the progression of
cancer cells via ablation of the de novo lipid synthesis and
induce apoptosis in cancer cells (Scheme 1).
■ CONCLUSIONS
This study reports a new concept that the PPNP platform
offers improved therapeutic benefit with gemcitabine in PanCa.
The data demonstrate that PPNPs and PPNPs/GEM
combination efficiently reduced proliferation and lipid
membrane structures of cancer cells. This improved response
was confirmed by inhibitory potential of lipid metabolism and
enhanced pro-apoptotic activity. The outcomes of this study
provide a novel molecular mechanism for enhanced chemo-
therapeutic efficacy of paclitaxel−gemcitabine combination in
PanCa. However, it remains a puzzle how to deliver both drugs
(paclitaxel and gemcitabine) in one nanoplatform to further
boost their therapeutic efficacy for PanCa treatment.
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